Pfizer Forecasts $54 Billion in Sales This Year as Demand for COVID-19 Vaccine and Treatment Pill Continues

1 year ago
Pfizer on Tuesday said it expects to see continued demand for its products this year, forecasting $54 billion in combined sales of its COVID-19 vaccine shots and antiviral pills. The American pharmaceutical and biotechnology giant said it expects to sell $32 billion of its vaccinations and $22 billion of its antiviral COVID-19 treatment pill Paxlovid in 2022 as demand for the products continues. Those numbers are based on contracts signed or close to being signed as of late January, Pfize...
Read Entire Article